IP Library Granted Patent US 7,294,473
Granted Patent B2
US 7,294,473 · App. 10/721,404 · Granted Nov 13, 2007

Methods of identifying substances that interact with JTT-1 protein

Assignee: Japan Tobacco Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,294,473
App. No.
10/721,404
Granted
Nov 13, 2007
Kind
B2
Abstract

Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.

Claims (18)

1. A method of identifying a substance that interacts with a polypeptide, the method comprising:

providing a purified polypeptide comprising (a) an extracellular region of the polypeptide set forth in SEQ ID NO:2, or (b) an extracellular region of a polypeptide that consists of the amino acid sequence of SEQ ID NO:2 in which one to ten amino acid residues are substituted, deleted or added, wherein the polypeptide comprises the amino acid sequence Phe-Asp-Pro-Pro-Pro-Phe (SEQ ID NO:21) and inhibits the activation of lymphocytes;

contacting the polypeptide with a test substance; and

determining whether the test substance interacts with the polypeptide.

2. The method of claim 1 , wherein the polypeptide is a fusion protein.

3. The method of claim 2 , wherein the fusion protein comprises a portion of a constant region of an immunoglobulin heavy chain.

4. The method of claim 1 , wherein the polypeptide comprises amino acid residues 1-140 of SEQ ID NO:2.

5. The method of claim 1 , wherein the test substance is a low molecular weight compound.

6. The method of claim 1 , wherein the test substance is a polypeptide.

7. The method of claim 1 , wherein the test substance is an antibody.

8. The method of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2.

9. The method of claim 8 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO:2.

10. The method of claim 9 , wherein the test substance is a low molecular weight compound.

11. The method of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2 in which one to ten amino acids are substituted, deleted or added, and wherein

(a) the polypeptide comprises the amino acid sequence Phe-Asp-Pro-Pro-Pro-Phe (SEQ ID NO:21) in its extracellular region,

(b) the polypeptide comprises the amino acid sequence Tyr-Met-Phe-Met (SEQ ID NO:22) in its cytoplasmic region, and

(c) an antibody reactive with the polypeptide induces proliferation of peripheral blood lymphocytes in the presence of an antibody reactive with CD3.

12. The method of claim 11 , wherein the test substance is a low molecular weight compound.

Priority Claims (2)
JP 9/62290 · Feb 27, 1997 · national
JP 10/62217 · Feb 26, 1998 · national
Continuity (4)
Continuation 1030105600 · Nov 21, 2002
Division 0938355100 · Aug 26, 1999
Continuation In Part PCTJP980083700 · Feb 27, 1998
Related Publication 20040229788A1 · Nov 18, 2004